Short answer
Sight Sciences, Inc. (SGHT) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $23M (up 19.5% year over year) with net income of −$4M.
Q2 2026 key financials · XBRL
- Revenue
- $23M
- +19.5% YoY · +18.7% QoQ
- Net income
- −$4M
- +62.8% YoY · +65.7% QoQ
- Operating margin
- -16.6%
- Gross margin
- 91.4%
- EPS (diluted)
- −$0.08
- +65.2% YoY · +66.7% QoQ
Source: XBRL data from the Sight Sciences, Inc. (SGHT) Q2 2026 10-Q on SEC EDGAR. USD.
Sight Sciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk-factor changes: No substantive Risk Factors text provided beyond 10-K cross-reference
- Reimbursement risk: Interventional Glaucoma coverage protection and broader Dry Eye reimbursement remain uncertain
- Regulatory risk: Extensive government regulation could affect product commercialization and operations
- Market risk: Competition from existing competitors and new entrants could hinder customer expansion
- Financial risk: Secured credit facility payment-term compliance remains a stated uncertainty
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sight Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.